Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial
Titel:
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial
Auteur:
Tao, Y. Biau, J. Sun, X.S. Sire, C. Martin, L. Alfonsi, M. Prevost, J.B. Modesto, A. Lafond, C. Tourani, J.M. Miroir, J. Kaminsky, M.C. Coutte, A. Liem, X. Chautard, E. Vauleon, E. Drouet, F. Ruffier, A. Ramee, J.F. Waksi, G. Péchery, A. Wanneveich, M. Guigay, J. Aupérin, A. Bourhis, J.